| Title |
LKB1/AMPK inhibits TGF-β1 production and the TGF-β signaling pathway in breast cancer cells
|
|---|---|
| Published in |
Tumor Biology, December 2015
|
| DOI | 10.1007/s13277-015-4639-9 |
| Pubmed ID | |
| Authors |
Nian-Shuang Li, Jun-Rong Zou, Hui Lin, Rong Ke, Xiao-Ling He, Lu Xiao, Deqiang Huang, Lingyu Luo, Nonghua Lv, Zhijun Luo |
| Abstract |
Adenosine monophosphate-activated protein kinase (AMPK) acts as a fuel gauge that maintains energy homeostasis in both normal and cancerous cells, and has emerged as a tumor suppressor. The present study aims to delineate the functional relationship between AMPK and transforming growth factor beta (TGF-β). Our results showed that expression of liver kinase B1 (LKB1), an upstream kinase of AMPK, impeded TGF-β-induced Smad phosphorylation and their transcriptional activity in breast cancer cells, whereas knockdown of LKB1 or AMPKα1 subunit by short hairpin RNA (shRNA) enhanced the effect of TGF-β. Furthermore, AMPK activation reduced the promoter activity of TGF-β1. In accordance, type 2 diabetic patients taking metformin displayed a trend of reduction of serum TGF-β1, as compared with those without metformin. A significant reduction of serum TGF-β1 was found in mice after treatment with metformin. These results suggest that AMPK inhibits the transcription of TGF-β1, leading to reduction of its concentration in serum. Finally, metformin suppressed epithelial-to-mesenchymal transition of mammary epithelial cells. Taken together, our study demonstrates that AMPK exerts multiple actions on TGF-β signaling and supports that AMPK can serve as a therapeutic drug target for breast cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 50 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 20% |
| Student > Master | 9 | 18% |
| Student > Ph. D. Student | 6 | 12% |
| Student > Doctoral Student | 4 | 8% |
| Researcher | 3 | 6% |
| Other | 6 | 12% |
| Unknown | 12 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 12 | 24% |
| Agricultural and Biological Sciences | 10 | 20% |
| Immunology and Microbiology | 4 | 8% |
| Medicine and Dentistry | 4 | 8% |
| Nursing and Health Professions | 2 | 4% |
| Other | 4 | 8% |
| Unknown | 14 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 January 2016.
All research outputs
#18,433,196
of 22,836,570 outputs
Outputs from Tumor Biology
#1,369
of 2,622 outputs
Outputs of similar age
#284,073
of 393,178 outputs
Outputs of similar age from Tumor Biology
#100
of 290 outputs
Altmetric has tracked 22,836,570 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,622 research outputs from this source. They receive a mean Attention Score of 2.2. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 393,178 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 290 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.